We first determined cell proliferation after knockdown of each gene (refer to the Supplementary Table S1 for siRNA sequence), respectively, in prostate cancer cell lines, 22Rv1 and LNCaP, both of which are reported to be at least partially androgen-dependent and express AR, the primary target of Abiraterone, CYP17A1 [34,35,36,37]. The gene discussed is CYP17A1; the disease is prostate carcinoma.